Safe Off-Label Use of Icatibant as Treatment for Acute Hereditary Angioedema Attacks in a Pediatric Patient
Bibliographic record
Abstract
Introduction Hereditary angioedema (HAE) is a rare, potentially life-threatening disease characterized by recurrent attacks of subcutaneous and submucosal swelling. Currently, only intravenous (IV) therapies are approved in the USA for treatment of HAE attacks in children younger than 12. IV therapy is difficult for caregivers to administer to young children, and these patients often require care in the emergency department (ED) for administration, delaying resolution. Subcutaneous injection allows earlier therapy, decreasing risk of more serious complications of acute attacks and reducing need for ED-level care. Icatibant is a selective antagonist of the bradykinin B2 receptor and administered subcutaneously. In the European Union (EU) and Canada, it is approved down to the age of 2. Here, we describe a single case of a 6-year-old female with HAE type 1 for whom icatibant was safely used off-label for an acute attack with resolution of her symptoms. Case Description Despite previous success with Berinert for abortion of peripheral attacks, this patient’s family was frustrated with long wait times and care in the ED. Given a sibling’s success with icatibant, review of preexisting literature, and the Canadian package insert, we opted to prescribe this off-label as a rescue using shared-decision making. She was initially given icatibant 0.4 mg/kg for abortive treatment in the ED. Eventually, the patient was approved through her insurance to use icatibant 15 mg SQ for attacks, and lanadelumab was also initiated for maintenance therapy given increasing attack frequency through manufacturer assistance and eventual insurance approval through assistance of a multidisciplinary team. The only adverse event was injection site pain, and her attack frequency decreased. Discussion This case illustrates the potential for safe off-label use of icatibant down to 2 years of age for acute attacks of HAE. Penn State Health has been prescribing and administering icatibant down to 2 years of age despite being off-label, and we hope this work encourages FDA approval and other institutions to make icatibant available as a weight-adjusted dose as an option for abortive treatment until oral rescue medications are available to reduce drug burden in pediatrics.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".